NDAORALTABLET
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
Indications (2)
Clinical Trials (5)
Anti-epileptogenic Effects of Eslicarbazepine Acetate
Started May 2019
Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
Started Dec 2016
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
Started Mar 2016
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Started Jun 2015
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
Started Apr 2012
254 enrolled
Partial Onset Seizures
Loss of Exclusivity
LOE Date
Aug 24, 2032
78 months away
Patent Expiry
Aug 24, 2032